EGFR mutation detection for targeted lung cancer therapy

Amoy Diagnostics offers a comprehensive portfolio of EGFR mutation detection kits designed to support precision oncology and guide treatment decisions for patients with non-small cell lung cancer (NSCLC). Among their trusted solutions, the EGFR 29 Mutations Detection Kit and the Super-ARMS® EGFR Mutation Detection Kit have been recommended by the National Institute for Health and Care Excellence (NICE) for detecting EGFR mutations to inform targeted therapy decisions. These kits are real-time PCR based assays and deliver accurate, reliable results with proven clinical utility, helping clinicians identify patients who may benefit from EGFR-targeted treatments.

Benefits of Amoy’s EGFR mutation detection kits

• High sensitivity: detect mutations with a sensitivity of 1%.
• Fast turnaround time: results in as little as 1.5 hours.
• Low sample input: require minimal sample input for testing.
• Versatile sample compatibility: optimised for both FFPE tissue and liquid biopsy samples.
• Supports personalised treatment: identify eligible patients for targeted therapies in non-small cell lung cancer (NSCLC).
• Cost-effective alternative to NGS, specifically designed for EGFR mutations, making it accessible to more laboratories.

Applications of Amoy’s EGFR mutation detection kits

• Non-small cell lung cancer (NSCLC) testing: Detect key EGFR mutations in NSCLC patients.
• Guiding targeted therapies: Support selection of personalised treatments based on EGFR mutation status.
• Liquid biopsy and tissue sample compatibility: suitable for both FFPE tissue and liquid biopsy samples.
• Comprehensive mutation detection: identify up to 31 different EGFR mutations for thorough patient analysis.